Core Viewpoint - The company, 精优药业, has entered into subscription agreements with three parties to issue new shares at a price of HKD 0.097 per share, which represents a discount to the market price on the date of the agreements [1][2][3] Group 1: Subscription Agreements - The company has signed Subscription Agreement I with subscriber I (曾广钊) to issue 30 million shares, representing approximately 1.26% of the existing issued share capital [1] - Subscription Agreement II was signed with subscriber II (张晓佳) for 20 million shares, equivalent to about 0.84% of the existing issued share capital [1] - Subscription Agreement III was established with subscriber III (Fudan Health International Ltd.) for 110 million shares, accounting for approximately 4.6% of the existing issued share capital [2] Group 2: Financial Implications - If all shares from Subscription Agreement I are successfully issued, the total proceeds will be approximately HKD 2.91 million, with a net amount of about HKD 2.89 million [3] - For Subscription Agreement II, the total proceeds are expected to be around HKD 1.94 million, with a net amount of approximately HKD 1.93 million [3] - The proceeds from Subscription Agreement III are projected to total about HKD 10.67 million, with a net amount of approximately HKD 10.60 million [3] Group 3: Use of Proceeds - The net proceeds from the subscriptions will be utilized for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [3] - The company aims to expand its health-related business opportunities into overseas markets while continuing to maintain and develop its existing pharmaceutical business through internal cash resources [3]